PBE vs. GERM
PBE (Invesco Dynamic Biotechnology & Genome ETF) and GERM (Amplify Treatments, Testing and Advancements ETF) are both Health & Biotech Equities funds - PBE tracks the Dynamic Biotech & Genome Intellidex Index (AMEX) while GERM tracks the Prime Treatments, Testing and Advancements Index. Both are passively managed. Over the past year, PBE returned 32.21% vs 0.00% for GERM. PBE charges 0.59%/yr vs 0.68%/yr for GERM.
Performance
PBE vs. GERM - Performance Comparison
Loading charts...
Returns By Period
PBE
- 1D
- 1.99%
- 1M
- 4.32%
- YTD
- 2.58%
- 6M
- 3.21%
- 1Y
- 32.21%
- 3Y*
- 11.28%
- 5Y*
- 3.46%
- 10Y*
- 7.59%
GERM
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- 0.00%
- 6M
- 0.00%
- 1Y
- 0.00%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
PBE vs. GERM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
PBE Invesco Dynamic Biotechnology & Genome ETF | 2.58% | 24.84% | -2.19% |
GERM Amplify Treatments, Testing and Advancements ETF | 0.00% | 0.00% | 0.00% |
PBE vs. GERM - Sectors Allocation Comparison
Sectors
PBE
GERM
Healthcare
Financial Services
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
PBE
GERM
Financial Services
PBE
GERM
Basic Materials
PBE
-
GERM
-
Communication Services
PBE
-
GERM
-
Consumer Cyclical
PBE
-
GERM
-
Consumer Defensive
PBE
-
GERM
-
Energy
PBE
-
GERM
-
Industrials
PBE
-
GERM
-
Real Estate
PBE
-
GERM
-
Technology
PBE
-
GERM
-
Utilities
PBE
-
GERM
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PBE vs. GERM — Risk / Return Rank
PBE
GERM
PBE vs. GERM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and Amplify Treatments, Testing and Advancements ETF (GERM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PBE | GERM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 1.30 | — | — |
| Calmar ratioReturn relative to maximum drawdown | 2.76 | — | — |
| Martin ratioReturn relative to average drawdown | 7.74 | — | — |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| PBE | GERM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.72 | — | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.15 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.31 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.33 | — | — |
Drawdowns
PBE vs. GERM - Drawdown Comparison
The maximum PBE drawdown since its inception was -45.69%, which is greater than GERM's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for PBE and GERM.
Loading charts...
Drawdown Indicators
| PBE | GERM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -45.69% | 0.00% | -45.69% |
Max Drawdown (1Y)Largest decline over 1 year | -11.73% | 0.00% | -11.73% |
Max Drawdown (3Y)Largest decline over 3 years | -22.43% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -34.71% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -37.84% | — | — |
Current DrawdownCurrent decline from peak | -1.71% | 0.00% | -1.71% |
Average DrawdownAverage peak-to-trough decline | -16.23% | 0.00% | -16.23% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.17% | 0.00% | +4.17% |
Volatility
PBE vs. GERM - Volatility Comparison
Invesco Dynamic Biotechnology & Genome ETF (PBE) has a higher volatility of 5.92% compared to Amplify Treatments, Testing and Advancements ETF (GERM) at 0.00%. This indicates that PBE's price experiences larger fluctuations and is considered to be riskier than GERM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PBE | GERM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.92% | 0.00% | +5.92% |
Volatility (6M)Calculated over the trailing 6-month period | 13.42% | 0.00% | +13.42% |
Volatility (1Y)Calculated over the trailing 1-year period | 18.79% | 0.00% | +18.79% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 22.55% | 0.00% | +22.55% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 24.92% | 0.00% | +24.92% |
PBE vs. GERM - Expense Ratio Comparison
PBE has a 0.59% expense ratio, which is lower than GERM's 0.68% expense ratio.
Dividends
PBE vs. GERM - Dividend Comparison
PBE's dividend yield for the trailing twelve months is around 1.03%, while GERM has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GERM Amplify Treatments, Testing and Advancements ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
PBE Invesco Dynamic Biotechnology & Genome ETF | 1.03% | 1.00% | 0.05% | 0.02% | 0.00% | 0.00% | 0.04% | 0.00% | 0.00% | 0.57% | 0.38% | 1.12% |
Frequently Asked Questions
PBE has higher volatility (5.92%) compared to GERM (0.00%). In terms of maximum drawdown, PBE dropped -45.69% vs GERM's 0.00%.
On 1-year performance, PBE leads with 32.21% vs 0.00% for GERM. On fees, PBE is cheaper at 0.59% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 1-year period, PBE has performed better with a 32.21% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
PBE is cheaper with a 0.59% expense ratio, compared with 0.68% for GERM.
PBE has the higher dividend yield at 1.03%, compared with 0.00% for GERM.
PBE tracks Dynamic Biotech & Genome Intellidex Index (AMEX), while GERM tracks Prime Treatments, Testing and Advancements Index. They also come from different issuers: Invesco and Amplify. Their fees differ too: 0.59% for PBE and 0.68% for GERM.
Find the right allocation for PBE and GERM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer